To improve venetoclax treatment outcomes, it was shown that a combination of venetoclax with other agents such as S63845, an MCL1 inhibitor, reduced the number of leukemic cells, indicating that MCL1 (S63845) and BCL-2 (venetoclax) inhibitors are synergistic and lead to T-ALL cell apoptosis [7]. This evidence concerns the gene MCL1 and acute lymphoblastic leukemia.